The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO 2019 | Blood first assay screening in treatment-naïve NSCLC: initial results from the ALK+ cohort

Name: Blood first assay screening in treatment-naïve NSCLC: initial results from the ALK+ cohort
Uploaded: 2019-09-28T00:00:00Z
Duration: 5 min 20 s
Description: Shirish Gadgeel, University of Michigan, Ann Arbor, MI, gives an update on the ALK+ cohort of the Blood First Assay Screening Trial (BFAST) in patients (pts) with treatment-naïve non-small cell lung cancer (NSCLC), comparing the results to the previous ALEX study (NCT02075840). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Shirish Gadgeel • 28 Sep 2019

ESMO 2019

Lung Cancer Non-Small Cell Lung Cancer Alectinib

ALEX BFAST

Shirish Gadgeel, University of Michigan, Ann Arbor, MI, gives an update on the ALK+ cohort of the Blood First Assay Screening Trial (BFAST) in patients (pts) with treatment-naïve non-small cell lung cancer (NSCLC), comparing the results to the previous ALEX study (NCT02075840). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.